Assembly Biosciences, Inc.

NasdaqGS:ASMB Stock Report

Market Cap: US$91.7m

Assembly Biosciences Future Growth

Future criteria checks 0/6

Assembly Biosciences's revenue and earnings are forecast to decline at 45.8% and 19.6% per annum respectively while EPS is expected to decline by 16.9% per annum.

Key information

-19.6%

Earnings growth rate

-16.9%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate-45.8%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Nov 2024

Recent future growth updates

Recent updates

Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers

Nov 13
Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers

Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely

Aug 17
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely

Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?

Feb 27
Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Nov 09
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Oct 05

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Jul 20

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jun 08
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jan 11
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Sep 03
We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences announces resignation of CFO

Jun 02

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Mar 24
Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

Feb 05
Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Dec 14
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Nov 16

Assembly Biosciences EPS beats by $0.69, beats on revenue

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqGS:ASMB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-101N/AN/A1
12/31/202616-87N/AN/A2
12/31/202533-58N/AN/A2
12/31/202428-41N/AN/A1
9/30/202428-412323N/A
6/30/202421-462424N/A
3/31/202413-512828N/A
12/31/20237-612223N/A
9/30/2023N/A-73-70-70N/A
6/30/2023N/A-81-76-76N/A
3/31/2023N/A-89-80-80N/A
12/31/2022N/A-93-85-84N/A
9/30/2022N/A-131-85-85N/A
6/30/20226-127-84-84N/A
3/31/20226-126-88-88N/A
12/31/20216-130-96-93N/A
9/30/20217-109-104-99N/A
6/30/202136-94-75-70N/A
3/31/202175-63-76-71N/A
12/31/202079-62-65-63N/A
9/30/202083-50-59-58N/A
6/30/202052-71-88-87N/A
3/31/202016-97-85-85N/A
12/31/201916-98-86-84N/A
9/30/201915-97-82-80N/A
6/30/201915-93-80-78N/A
3/31/201915-102-75-73N/A
12/31/201815-91-65-65N/A
9/30/201814-68-58-58N/A
6/30/201813-58N/A-52N/A
3/31/201812-45N/A-49N/A
12/31/20179-43N/A2N/A
9/30/20176-51N/A1N/A
6/30/20173-51N/A4N/A
3/31/20171-47N/A9N/A
12/31/2016N/A-44N/A-35N/A
9/30/2016N/A-40N/A-29N/A
6/30/2016N/A-36N/A-27N/A
3/31/2016N/A-32N/A-24N/A
12/31/2015N/A-28N/A-19N/A
9/30/2015N/A-27N/A-17N/A
6/30/2015N/A-31N/A-16N/A
3/31/2015N/A-27N/A-13N/A
12/31/2014N/A-24N/A-15N/A
9/30/2014N/A-24N/A-17N/A
6/30/2014N/A-17N/A-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ASMB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ASMB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ASMB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ASMB's revenue is expected to decline over the next 3 years (-45.8% per year).

High Growth Revenue: ASMB's revenue is forecast to decline over the next 3 years (-45.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ASMB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 23:01
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Assembly Biosciences, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Raymond DeaconBrean Capital
Madhu KumarB. Riley Securities, Inc.